Impact of High-Dose Statin Pretreatment in Patients with Stable Angina during Off-Pump Coronary Artery Bypass
| Autor: | Seong Yong Park, Yoo-Hwa Hwang, Young-Nam Youn, Huyn-Chul Joo, Kyung-Jong Yoo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Statin medicine.drug_class medicine.medical_treatment Coronary artery bypass Off-pump Creatine chemistry.chemical_compound Clinical Research Internal medicine medicine Clinical endpoint Rosuvastatin Off-pump coronary artery bypass Troponin T business.industry nutritional and metabolic diseases Surgery medicine.anatomical_structure chemistry Cardiothoracic surgery Cardiology Cardiology and Cardiovascular Medicine business medicine.drug Artery |
| Zdroj: | The Korean Journal of Thoracic and Cardiovascular Surgery |
| ISSN: | 2093-6516 2233-601X |
| Popis: | Background: Periprocedural treatment with high-dose statins is known to have cardioprotective and pleiotropic effects, such as anti-thrombotic and anti-inflammatory actions. We aimed to assess the efficacy of high-dose rosuvastatin loading in patients with stable angina undergoing off-pump coronary artery bypass grafting (OPCAB). Materials and Methods: A total of 142 patients with stable angina who were scheduled to undergo surgical myocardial revascularization were randomized to receive either pre-treatment with 60-㎎ rosuvastatin (rosuvastatin group, n=71) or no pre-treatment (control group, n=71) before OPCAB. The primary endpoint was the 30-day incidence of major adverse cardiac events (MACEs). The secondary endpoint was the change in the degree of myocardial ischemia as evaluated with creatine kinase-myocardial band (CK-MB) and troponin T (TnT). Results: There were no significant intergroup differences in preoperative risk factors or operative strategy. MACEs within 30 days after OPCAB occurred in one patient (1.4%) in the rosuvastatin group and four patients (5.6%) in the control group, respectively (p=0.37). Preoperative CK-MB and TnT were not different between the groups. After OPCAB, the mean maximum CK-MB was significantly higher in the control group (rosuvastatin group 10.7±9.75 ng/mL, control group 14.6±12.9 ng/mL, p=0.04). Furthermore, the mean levels of maximum TnT were significantly higher in the control group (rosuvastatin group 0.18±0.16 ng/mL, control group 0.39±0.70 ng/mL, p=0.02). Conclusion: Our findings suggest that high-dose rosuvastatin loading before OPCAB surgery did not result in a significant reduction of 30-day MACEs. However, high-dose rosuvastatin reduced myocardial ischemia after OPCAB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|